Medpace (MEDP) Stock: Buy, Sell, or Hold?
MEDP - Medpace Holdings, Inc. Common Stock
$599.47
1.39 (0.23%)
â˛
5d:
-3.14%
30d:
+1.09%
90d:
+6.08%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 21, 2026
16d
Get Alerted When MEDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MEDP is fairly priced but lacks strong directional signals. At 2.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MEDP is fairly priced but lacks strong directional signals. At 2.8% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$662.49
Based on 6.6% avg growth
INTRINSIC VALUE TODAY
$411.36
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MEDP is currently trading at $599.47, which is considered fair relative to its 30-day fair value range of $592.06 to $620.71. The stock's valuation (Forward PE: 31.0) is in line with its historical norms (28.6). At these levels, the market is pricing in 2.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MEDP is in a strong uptrend. The price is currently testing key support at $587.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MEDP is in a strong uptrend. The price is currently testing key support at $587.38. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 43/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$592.06 -
$620.71
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
74.6%
Protect Your Profits
Holding MEDP? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (43/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($589.92)
- NEUTRAL: Market pricing in 2.8% annual earnings growth - fairly valued
- WARNING: Composite score 38/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$592.06 -
$620.71
Current vs Trading Range
FAIR
Expected Move (7 Days)
Âą$43.38
(7.2%)
Support & Resistance Levels
Support Level
$587.39
Resistance Level
$637.65
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
31.04
Wall Street Target
$589.92
(-1.6%)
Revenue Growth (YoY)
17.2%
Earnings Growth (YoY)
37.1%
Profit Margin
17.7%
Valuation Premium vs History
+2.8% premium
PE vs Historical
31.0 vs 28.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.8%
(market-implied from PE analysis)
1-Year Target
$616.26
(+3%)
2-Year Target
$633.51
(+6%)
3-Year Target
$651.25
(+9%)
3-Yr Target (if PE normalizes)
(PE: 31â29)
PE COMPRESSION
$599.97
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.0, Growth: 9.1%)
$777.79
(+30%)
Base:
(SPY PE: 20.4, Growth: 9.1%)
$511.10
(-15%)
Bear:
(PE: 17.3, Growth: 9.1%)
$434.44
(-28%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (35x PE), but valuation improves significantly next year (31x PE) as earnings recover.
Trailing PE: 35.10 | Current EPS (TTM): $17.04
Bull Case
$745.53
(+24%)
Analyst growth 13.3%, PE expands to 38.6
Base Case
$677.76
(+13%)
Market implied 13.3%, PE stable at 35.1
Bear Case
$406.69
(-32%)
Severe decline -20.0%, PE contracts to 29.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 03, 2026 9:06 PM ET
Data refreshes hourly during market hours. Next update: 10:06 PM
Data refreshes hourly during market hours. Next update: 10:06 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MEDP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$653 | 49 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$231 | 53 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$196 | 48 HOLD |
|
LH
Laboratory Corporation oâĻ |
STRONG BUY
20 analysts |
$345 | 67 BUY |
Advanced MEDP Option Strategies
Professional options setups generated by AI based on today's MEDP price and gamma walls.
